– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin...
“ Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months “ “ Topline data expected in early 2025 “ “ Breakthrough Therapy Designation to enable expedited review by FDA “ SAN...
“ Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML “ “ Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 “ “ Positive...
“ Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML “ “ Registration-directed trial of ziftomenib in NPM1-mutant AML on track to...
KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML SAN DIEGO, Feb. 26, 2024 (GLOBE...
“ No differentiation syndrome events reported “ “ 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML “ “ 56% CR/CRh with ven/aza in menin inhibitor na¯ve patients with R/R AML “ “ 80%...
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
SAN DIEGO, June 11, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial of the Company’s potent and selective menin inhibitor, ziftomenib, including significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).
â“ Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA â“ â“ Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting